Revium Rx reported net income of -$0.75M for the quarter ended Jun 2026. This income statement covers 4 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2024 | Jun2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|
| Operating items | ||||
| Research & DevelopmentR&D | 0.39M | 0.44M | ||
| Selling, General & AdministrativeSG&A | 0.55M | 0.29M | ||
| Operating ExpensesOpex | 0.94M | 0.73M | ||
| Operating IncomeOp. Inc | -0.94M | -0.73M | ||
| EBIT | -0.94M | -0.73M | ||
| Non-operating items | ||||
| Other Non Operating IncomeOther Non Op Inc. | -0.10M | -0.02M | ||
| Net income details | ||||
| EBT | -0.94M | -0.73M | ||
| Profit After TaxPAT | -1.04M | -0.75M | ||
| Income from Continuing OperationsIncome (Continuing) | -0.94M | -0.73M | ||
| Consolidated Net IncomeConsol Net Inc. | -0.94M | -0.73M | ||
| Income towards Parent CompanyParent Net Inc | -0.94M | -0.73M | ||
| Net Income towards Common StockholdersNet Income | -0.94M | -0.73M | ||
| Additional items | ||||
| EPS (Basic) | -0.02 | -0.01 | ||
| EPS (Diluted) | -0.02 | -0.01 | ||
| Shares Outstanding | 57.93M | 60.73M | 60.73M | 60.73M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 57.93M | 60.73M | 60.73M | 60.73M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 60.73M | 60.73M | 60.73M | 60.73M |
| EBITDA | -0.94M | -0.73M |